“Cancer remains one of humanity’s most intractable diseases, and is expected to surpass heart disease as the leading annual cause of American fatalities by 2030.” Utilization of guideline-recommended cancer screening paradigms allows for timely initiation of therapy and superior clinical outcomes for many patients. However, only four screening methodologies are guideline-recommended, and patient adherence to regular screening is suboptimal. Cancers responsible for 71% of cancer deaths have no recommended screening methodologies.

Technical advances in next-generation sequencing and machine learning algorithms have transformed our ability to detect cancer-derived cell-free DNA in the blood. Utilization of minimally-invasive blood-based assays that can detect and localize multiple cancers have the potential to dramatically improve the efficiency of cancer detection. This activity will provide an overview of trial data related to the development of a blood-based multi-cancer early detection test.

Speaker: Brenda Wood, PharmD

This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

** IMPORTANT: AMCP webinars are limited to the first 1000 that join the webinar. The recording and slides of sponsored webinars will be provided if permitted by the sponsor.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.